BLife Therapeutics intends to launch clinical trials of AP-003 to test the efficacy of IFNa2b for treatment of COVID-19
Blife Therapeutics intends to launch clinical trials to test the efficacy of IFNa2b for treatment of Covid 19. AP-003 is being developed as a novel interferon alpha2b (IFNa2b) inhalation formulation.
IFNa2b has been used to treat COVID 19 in China.²
Subject to receiving marketing authorization, AP-003 could potentially be used to treat patients early after COVID 19 infection which may potentially prevent the progression to severe disease and need for hospitalization.³
If successful in clinical trials, AP-003 may potentially be positioned as an initial treatment for COVID 19 and similar viruses.
For more information please see the full investor presentation.
- Subject to successful outcome of clinical trials and obtaining market authorization
- Dong et al, 2020; Lu, 2020; Shen & Yang, 2020; Zhou et al, 2020
- Altum Clin Protocol ALT 003 COV 01 2020 04 30
SARS CoV 2 coronavirus causes COVID 19. SARS CoV viruses block interferon production in infected cells, allowing the virus to continue replicating unabated ¹.
Treatment with interferon may overcome that block, potentially restoring cells normal anti viral activity.
Interferon alpha 2b (IFNa2b) is a potential treatment for COVID 19 ².
IFNa2b (inhaled) has been used in China on COVID 19 patients.
AP-003 may be given by inhalation at the first signs of COVID 19 with following projected outcomes according to Altum Clin Protocol ALT 003 COV 01 2020 05 04 rationale:
- AP-003 inhalation applies INFa2b directly to the lungs which may enable infected cells to halt viral replication.
- AP-003 inhalation may help to restore the initial immune response to COVID 19.
- AP-003 inhalation 1st proposed target indication: people at higher risk to develop severe COVID 19 disease
- Potential Result: Reduction of the overall hospitalization rate, long term tissue damage and death by reducing the severity of the disease
- Potential prevention of long term damage to the lung, heart, kidney and the brain
Response to Viral Infection
Typical Response to Viral Infection
When a virus invades a cell, interferon is produced resulting in inhibition of viral replication. The Immune response proceeds to eradicate remaining virus in an orderly fashion, without damaging normal tissues.
When COVID-19 invades a cell, interferon production is thought to be blocked resulting in uncontrolled viral replication. By the time the immune system responds to the large viral load, there is already viral-related tissue damage. A massive outpouring of cytokines and antibodies believed to create a ‘cytokine storm’ causing extensive further tissue damage.
Administration of AP-003 may bypass interferon blockade in the cells and may restore IFN inhibition of viral replication so there is a normal immune response.
BLife Therapeutics is a subsidiary of Better Life Pharmaceuticals Inc., a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Our shares are publicly-traded on the CNX under the ticker symbol “BETR” and on the OTCQB under the ticker symbol “PVOTF”
BLife Therapeutics Investor Presentation
Mon May 12, 2020 – The Globe and Mail
Mon May 11, 2020 – Medscape
Fri May 8, 2020 – New York Times
The May 7, 2020
Our Leadership Team
BetterLife has assembled a highly experienced management team that has clinical, commercial, product development and financial experience
Risk Factors and Cautionary Note
This website contains statistical data, market research, website links, third party publications and industry forecasts that were obtained from government or other third party publications and reports or based on estimates derived from such publications and reports and management’s knowledge of, and experience in, the markets in which the Corporation operates. Government and industry publications and reports generally indicate that they have obtained their information from sources believed to be reliable, but do not guarantee the accuracy and completeness of their information. None of the authors of such publications and reports has provided any form of consultation, advice or counsel regarding any aspect of, or is in any way whatsoever associated with, this website. Actual outcomes may vary materially from those forecast in such reports or publications, and the prospect for material variation can be expected to increase as the length of the forecast period increases. While management believes this data to be reliable, market and industry data is subject to variations and cannot be verified due to limits on the availability and reliability of data inputs, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. Accordingly, the accuracy, currency and completeness of this information cannot be guaranteed. The Corporation has not independently verified any of the data from third party sources referred to in this website or ascertained the underlying assumptions relied upon by such sources. Further, statements as to the past performance and studies are not necessarily indicative of or guarantees of future performance or success or the commercial viability of any successful trial and there is no representation, warranty or assurance that the Corporation will achieve similar results or success and readers should not place undue reliance on such statements.
The Corporation is not making any express or implied claims that AntiCovir or any other product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time. Further, the safety and efficacy of AntiCovir are under investigation and market authorization has not yet been obtained.
Except for historical information, the matters set forth in this website be forward-looking statements that involve risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to complete the transaction with Altum or to meet obligations under the agreement with Altum, the failure of Altum to complete Phase 3 trials or to have success in such trials, the failure of Altum to secure and/or enforce patent protection for AntiCovir, the failure of Altum to secure exclusive rights from third parties, the failure of the Company to secure financing needed to carry out the plans set out herein, the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of BetterLife’s products, statements with respect to internal expectations, the competitive environment within the industry, the ability of BetterLife to commence and expand its operations, the level of costs incurred in connection with BetterLife’s operational efforts, economic conditions in the industry, pandemics, and the financial strength of BetterLife’s future customers and suppliers. Reliance should not be placed on forward-looking statements, as they involve known and unknown risks, uncertainties and other factors that may cause the actual results to differ materially from the anticipated future results expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those set forward in the forward-looking statements include, but are not limited to: our ability to obtain, on satisfactory terms or at all, the capital required for research, product development, operations and marketing; general economic, business and market conditions; our ability to successfully and timely complete clinical studies; product development delays and other uncertainties related to new product development; our ability to attract and retain business partners and key personnel; · the risk of our inability to profitably commercialize our proposed products; the risk that our proposed clinical trials will not be launched in a timely manner (or at all) or if launched yield positive results or that we will not obtain regulatory market approvals for our products; the extent of any future losses; the risk of our inability to establish or manage manufacturing, development or marketing collaborations; the risk of delay of, or failure to obtain, necessary regulatory approvals and, ultimately, product launches; dependence on third parties for successful commercialization of our products; inability to obtain product and raw materials in sufficient quantity or at standards acceptable to health regulatory authorities to commence and complete clinical trials or to meet commercial demand; the risk of the termination or conversion of our license with Altum or our inability to enforce our rights under our license with Altum;· our ability to obtain patent protection and protect our intellectual property rights; commercialization limitations imposed by intellectual property rights owned or controlled by third parties; uncertainty related to intellectual property liability rights and liability claims asserted against us; the impact of competitive products and pricing; and future levels of government funding; additional risks and uncertainties, many of which are beyond our control. See “Risk Factors” in the Investor Presentation.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Shareholders and other Corporation stakeholders are encouraged to only look to the formal disclosure record under the Corporation’s issuer profile at www.sedar.com and on the Corporation’s website at abetterlifepharma.com for material information regarding the Corporation.